Abstract
Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Current Pharmaceutical Design
Title:Microvasculature Recovery by Angiogenesis After Myocardial Infarction
Volume: 24 Issue: 25
Author(s): Lina Badimon and Maria Borrell*
Affiliation:
- CIBER-CV, Instituto de Salud Carlos III, Madrid,Spain
Keywords: Angiogenesis, reperfusion therapies, microvascular dysfunction, myocardial infarction, myocardial perfusion, ischemia.
Abstract: Advances in early reperfusion therapies focused on the revascularization of the ischemic tissues, in the last decades, lead to reduced mortality in acute myocardial infarction (MI) patients. However, a large proportion of patients show inadequate myocardial perfusion because of dysfunction of the microcirculation. The high prevalence of microvascular dysfunction after reperfusion therapies and the negative prognostic of this procedure justify the search for therapeutic strategies that aim to restore the microvascular network. It is well known that the size of the initial infarct, the duration of ischemia and the efficiency of reperfusion determine myocardial tissue damage and cardiomyocyte loss after myocardial infarction. Therefore any advancement on the mechanisms that induce the repair process of microvascular dysfunction after reperfused MI is of great interest. Here, we will review the different proteins and cells known to participate in angiogenesis induction post-MI and we will also discuss the potential pharmacological and cellular processes that promote the recovery of microvasculature by angiogenesis stimulation after MI.
Export Options
About this article
Cite this article as:
Badimon Lina and Borrell Maria *, Microvasculature Recovery by Angiogenesis After Myocardial Infarction, Current Pharmaceutical Design 2018; 24 (25) . https://dx.doi.org/10.2174/1381612824666180629162726
DOI https://dx.doi.org/10.2174/1381612824666180629162726 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Age- Related Macular Degeneration
Current Drug Therapy The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Glucose Metabolism and Insulin Resistance in Sepsis
Current Pharmaceutical Design Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Human Chorionic Gonadotropin: A Model Molecule For Oligopeptide-Based Drug Discovery
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Essential Roles of Toll-Like Receptors in Atherosclerosis
Current Medicinal Chemistry Novel Oral Anticoagulants in the Treatment of Acute Coronary Syndromes: Is there any Room for New Anticoagulants?
Current Clinical Pharmacology Chronic Complications of Diabetes Mellitus: A Mini Review
Current Diabetes Reviews Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Screening, Evaluation, and Early Management of Acute Aortic Dissection in the ED
Current Cardiology Reviews Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Mechanisms of Cardioprotection of Halogenated Agents During Extracorporeal Circulation in Cardiac Surgery
Current Vascular Pharmacology Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Aldose Reductase for the Treatment of Cancer
Current Cancer Drug Targets Nothing But Stress – The Interplay of Angiotensin II, Inflammation, Hypertension and Atherosclerosis: Implications for Atherosclerotic Plaque Stability
Vascular Disease Prevention (Discontinued) Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry